UY34496A - Formulacion nasal - Google Patents

Formulacion nasal

Info

Publication number
UY34496A
UY34496A UY0001034496A UY34496A UY34496A UY 34496 A UY34496 A UY 34496A UY 0001034496 A UY0001034496 A UY 0001034496A UY 34496 A UY34496 A UY 34496A UY 34496 A UY34496 A UY 34496A
Authority
UY
Uruguay
Prior art keywords
nasal formulation
formulation
nasal
azelastine
cosolvent
Prior art date
Application number
UY0001034496A
Other languages
English (en)
Inventor
Xian-Ming Zeng
Mukul C Dalvi
Jade Ching-Ying Ly
Original Assignee
Teva Branded Pharmaceutical Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Branded Pharmaceutical Products Inc filed Critical Teva Branded Pharmaceutical Products Inc
Publication of UY34496A publication Critical patent/UY34496A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención se relaciona con una formulación de solución para la administración nasal que comprende azelastina, dipropionato de beclometasona, un cosolvente, un ácido y un propelente de HFA.
UY0001034496A 2011-12-07 2012-12-06 Formulacion nasal UY34496A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161567893P 2011-12-07 2011-12-07
GBGB1121812.0A GB201121812D0 (en) 2011-12-07 2011-12-19 NAsal formulation

Publications (1)

Publication Number Publication Date
UY34496A true UY34496A (es) 2014-05-30

Family

ID=48693842

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034496A UY34496A (es) 2011-12-07 2012-12-06 Formulacion nasal

Country Status (15)

Country Link
US (1) US20130167838A1 (es)
EP (1) EP2788001B1 (es)
AR (1) AR089101A1 (es)
CA (1) CA2856043C (es)
DK (1) DK2788001T3 (es)
ES (1) ES2560029T3 (es)
GB (1) GB201121812D0 (es)
HK (1) HK1200342A1 (es)
HU (1) HUE026612T2 (es)
IL (1) IL232944A0 (es)
MX (1) MX2014006769A (es)
PL (1) PL2788001T3 (es)
TW (1) TWI468193B (es)
UY (1) UY34496A (es)
WO (1) WO2013083569A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2906008C (en) 2013-03-13 2019-07-09 Flatley Discovery Lab, Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis
GB201408229D0 (en) 2014-05-09 2014-06-25 Norton Waterford Ltd Aerosol device

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9805938D0 (en) 1998-03-19 1998-05-13 Glaxo Group Ltd Valve for aerosol container
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
TW200522932A (en) 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
JP2008534509A (ja) * 2005-03-23 2008-08-28 エラン ファーマ インターナショナル リミテッド ナノ粒子副腎皮質ステロイドおよび抗ヒスタミン薬の製剤
CA2661129A1 (en) * 2006-08-22 2008-02-28 Glaxo Group Limited Actuator for an inhaler
GB0719257D0 (en) * 2007-10-04 2007-11-14 3M Innovative Properties Co Metered dose dispenser
GB0721739D0 (en) * 2007-11-06 2007-12-19 3M Innovative Properties Co medicinal inhalation devices and components thereof
ES2712996T3 (es) * 2010-10-12 2019-05-17 Ivax Pharmaceuticals Ireland Dispositivo de pulverización nasal

Also Published As

Publication number Publication date
EP2788001B1 (en) 2015-12-02
IL232944A0 (en) 2014-07-31
US20130167838A1 (en) 2013-07-04
WO2013083569A1 (en) 2013-06-13
GB201121812D0 (en) 2012-02-01
AR089101A1 (es) 2014-07-30
CA2856043C (en) 2017-01-17
DK2788001T3 (en) 2016-02-01
PL2788001T3 (pl) 2016-04-29
HUE026612T2 (hu) 2016-06-28
TW201330879A (zh) 2013-08-01
ES2560029T3 (es) 2016-02-17
CA2856043A1 (en) 2013-06-13
EP2788001A1 (en) 2014-10-15
HK1200342A1 (zh) 2015-08-07
MX2014006769A (es) 2015-01-16
TWI468193B (zh) 2015-01-11

Similar Documents

Publication Publication Date Title
CY1122786T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
CR20130556A (es) FORMULACIÓN PARA ANTICUERPO ANTI-a4ß7
CR20130663A (es) Composiciones farmcéuticas inhalables
ECSP15013227A (es) Formulaciones acuosas estables de adalimumab
CR20150326A (es) Inhibidores de autotaxina
CL2018000705A1 (es) Método de cristalización y biodisponibilidad
BR112014030714A2 (pt) composto de lipídeo ionizável , composições , carreador de fármaco , formulação farmacêutica e método de entrega de um fármaco
CR20140321A (es) Sistema de administracion transdermica que contiene buprenofina
UY34698A (es) Combinaciones farmacéuticas que comprenden un análogo de tionucleótidos
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
EA201600495A1 (ru) Пролекарство адреномедуллина на основе полиэтиленгликоля и его применение
CL2014000995A1 (es) Composicion de prodroga que comprende un conjugado de hidromorfona y un acido arilcarboxilico; un método para tratar un paciente que comprende la administracion de la composicion.
BR112013012587A2 (pt) composição farmacêutica para administração nasal
IT1402018B1 (it) Formulazioni per il trattamento delle affezioni delle prime vie respiratorie.
GT201400090A (es) 2-tiopirimidinonas
BR112013016241A2 (pt) composto, e, método para fabricar um composto
BRPI1007732A2 (pt) aparelho para administração de medicamentos para a administração de um aerossol incluindo um medicamento para um paciente, kit para a administração de um aerossol incluindo um medicamento para um paciente e método de administração de um aerossol incluindo um medicamento para um paciente
CL2017000394A1 (es) Composición que contiene cineol para la administración nasal
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
CL2014003055A1 (es) Procedimiento para preparar una composicion farmaceutica que comprende i) proporcionar una primera combinacion que comprende un compuesto inhibidor del proteasoma peptidico, una o mas ciclodextrinas y agua, y ii) poner en contacto la primera combinacion con un acido para formar una segunda combinacion; composicion farmaceutica.
MY193312A (en) Topical formulation for promoting wound healing
CO2017007316A2 (es) Formulación farmacéutica
ECSP12011618A (es) Procedimiento para la elaboración de un jarabe farmacéutico-veterinario que comprende omeprazol
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020